DrugPatentWatch

Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Tradename: TEMODAR

Summary for Tradename: TEMODAR

Patents:4
Applicants:1
NDAs:2
Suppliers: see list3
drug
patent expirations by year for
 TEMODAR

Pharmacology for Tradename: TEMODAR

Drug ClassAlkylating Drug
Mechanism of ActionAlkylating Activity

Clinical Trials for: TEMODAR

Gliadel Wafers and Temodar in the Treatment of Glioblastoma Multiforme
Status: Terminated Condition: Primary Glioblastoma Multiforme

Gliadel, XRT, Temodar, Avastin Followed by Avastin, Temodar for Newly Diagnosed Glioblastoma Multiforme (GBM)
Status: Active, not recruiting Condition: Glioblastoma Multiforme; Gliosarcoma

Study of Bevacizumab Plus Temodar and Tarceva in Patients With Glioblastoma or Gliosarcoma
Status: Active, not recruiting Condition: Glioblastoma; Gliosarcoma

Ph. II Temozolomide + O6-BG in Treatment of Pts w Temozolomide-Resistant Malignant Glioma
Status: Completed Condition: Glioblastoma Multiforme; Anaplastic Glioma

Sarasar and Temodar for Glioblastoma Multiforme Patients
Status: Active, not recruiting Condition: Glioblastoma Multiforme; Gliosarcoma; Brain Tumors

Temodal (Temozolomide) Post Marketing Surveillance Protocol (Study P05557AM2)
Status: Completed Condition: Glioblastoma; Glioma; Astrocytoma

Avastin/Radiation (XRT)/Temozolomide (Temodar) Followed by Avastin/Temodar/Topotecan for Glioblastoma
Status: Active, not recruiting Condition: Malignant Glioma; Glioblastoma Multiforme; Gliosarcoma

Safety and Tolerability of Carboxyamidotriazole Orotate (CTO) in Solid Tumors or With TemodarĀ® in Glioblastoma or Other Recurrent Malignant Gliomas or in Combination With TemodarĀ® and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant Gliomas
Status: Recruiting Condition: Solid Tumors, Glioblastoma, Recurrent Malignant Gliomas

Study of Vismodegib in Combination With Temozolomide Versus Temozolomide Alone in Patients With Medulloblastomas With an Activation of the Sonic Hedgehog Pathway
Status: Recruiting Condition: Histologically Confirmed Medulloblastoma; Activation of the Sonic Hedgehog (SHH) Pathway

Avastin in Combination With Radiation (XRT) & Temozolomide, Followed by Avastin, Temozolomide and Irinotecan for Glioblastoma (GBM) and Gliosarcomas
Status: Active, not recruiting Condition: Glioblastoma; Gliosarcoma; Brain Tumor

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Merck Sharp Dohme
TEMODAR
temozolomide
CAPSULE;ORAL021029Aug 11, 1999RXNo5,260,291*PED<disabled>Y<disabled>
Merck Sharp Dohme
TEMODAR
temozolomide
CAPSULE;ORAL021029Aug 11, 1999RXYes5,260,291*PED<disabled>Y<disabled>
Merck Sharp Dohme
TEMODAR
temozolomide
CAPSULE;ORAL021029Oct 19, 2006RXNo5,260,291*PED<disabled>Y<disabled>
Merck Sharp Dohme
TEMODAR
temozolomide
POWDER;INTRAVENOUS022277Feb 27, 2009RXYes5,260,291*PED<disabled>Y<disabled>
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: TEMODAR

Drugname Dosage Strength RLD Submissiondate
temozolomideCapsules140 mg and 180 mgTemodar3/24/2008

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology

`abc